Shailender Bhatia, M.D.
Shailender Bhatia, M.D.
Associate Member
Clinical Research Division, Fred Hutch
Dr. Shailender Bhatia aims to improve outcomes for people with kidney cancers and skin cancers, especially melanoma and Merkel cell carcinoma. He leads clinical trials of new immunotherapies and targeted, less-toxic therapies for patients with these diseases.
Research Interests
Dr. Bhatia’s research efforts are mostly focused on clinical trials that aim at improving outcomes in skin cancers (especially Melanoma and Merkel cell carcinoma). He is especially interested in those novel therapeutic approaches that stimulate the immune system against cancer and those that target therapy to the tumors in order to spare unnecessary toxicity.
Active Clinical Trials
Adjuvant Avelumab in Merkel Cell Cancer (ADAM)
Study Number: 9820
Phase: III
Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Study Number: 1256914
Phase: I
A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358)
Study Number: 20152209
Phase: I/II
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma
Study Number: RG1003448
Phase: II
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
Study Number: RG1718055
Phase: III
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody Administered Alone and in Combination with Nivolumab in Advanced Solid Tumors
Study Number: UW15057
Phase: I/IIa
Dr. Bhatia in the News
For the Media
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email media@fredhutch.org or call 206.667.2210.